Multiple Myeloma in 2022 and Beyond

Clinical experts from the US discuss current treatment strategies and emerging therapies, including MRD, IMiDs, proteasome inhibitors, and immunotherapy approaches

September 23 and 24, 2022

Faculty Chair

Rafael Fonseca, MD

Mayo Clinic, Phoenix, AZ, US

Faculty Members

Leif Bergsagel, MD, FASCO
Mayo Clinic, Phoenix, AZ, US

Saurabh Chhabra, MBBS, MD
Mayo Clinic, Phoenix, AZ, US

Andrzej Jakubowiak, MD, PhD
University of Chicago, IL, US

Ajai Chari, MD
Mount Sinai New York, NY, US

Gareth Morgan, MD, PhD, FRCP, FRCPath
Perlmutter Cancer Center, New York, NY, US

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Frontline Transplant-Eligible MM
  • Frontline Transplant-Ineligible MM
  • MRD, Maintenance, and Consolidation Update
  • The Continued Role of Immunomodulatory Agents (IMiDs) and Proteasome Inhibitors (PIs)
  • Next-Generation Small Molecules: BCL2, XPO1, BCMA Inhibitors, and Beyond
  • CAR T Therapies for the Treatment of MM
  • Bispecific Agents for the Treatment of MM

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.